Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 590 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: PUSH Clear all
Completed Phase 1Phase 2 Interventional Results available

Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis

NCT01860170
View directory record Official record
Conditions
Hematological Malignancy
Interventions
Cohort 1-Bortezomib (Velcade ®), Cohort 2-Bortezomib (Velcade ®), Cohort 3-Bortezomib (Velcade ®)
Drug
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 18, 2026, 5:06 AM EDT
Completed Not applicable Interventional

Improving Blood Pressure Control Through the myBPmyLife mHealth Application

NCT05154929
View directory record Official record
Conditions
Hypertension
Interventions
Dietary and physical activity JITAI delivered through the myBPmyLife app, Control Group
Behavioral · Other
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Ann Arbor, Michigan • Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 20, 2024 · Synced Oct 18, 2026, 5:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Examining Yoga's Effects on Smoking

NCT02181179
View directory record Official record
Conditions
Yoga, Waitlist
Interventions
Yoga
Behavioral
Lead sponsor
Jasper A. Smits
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 18, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT02277197
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck
Interventions
Ficlatuzumab, Cetuximab
Drug
Lead sponsor
James J Lee
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Oct 18, 2026, 5:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Exploring Predictors of Response to a Peer-Mediated Intervention for Preschoolers With ASD

NCT05277103
View directory record Official record
Conditions
Autism Spectrum Disorder, Nonverbal Communication
Interventions
Exploring predictors of response to a peer-mediated communication intervention for minimally verbal preschoolers with ASD
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
3 Years to 6 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 18, 2026, 5:06 AM EDT
Completed Not applicable Interventional Results available

AAT + tDCS to Reduce Cue-induced Craving and Smoking Behavior

NCT05426460
View directory record Official record
Conditions
Smoking Behaviors, Smoking, Cigarette
Interventions
Approach/Avoidance Task, Transcranial Direct Current Stimulation, AC, Sham tDCS
Behavioral · Device
Lead sponsor
Cynthia Conklin
Other
Eligibility
26 Years to 55 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 18, 2026, 5:06 AM EDT
Completed No phase listed Observational

Idiopathic Parkinson's Progression and Dopamine Transporter SPECT

NCT03531086
View directory record Official record
Conditions
Parkinson Disease
Interventions
Ioflupane I 123
Drug
Lead sponsor
Julie Gurwell
Other
Eligibility
40 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Oct 18, 2026, 5:06 AM EDT
Terminated Phase 2 Interventional Results available

Chemotherapy Based on PET Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

NCT01390584
View directory record Official record
Conditions
Lymphoma
Interventions
Doxorubicin, Bleomycin, Vinblastine, PET, INRT, Dacarbazine, Etoposide, Cyclophosphamide, Vincristine, Procarbazine, Prednisone
Drug · Diagnostic Test · Radiation
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Stanford, California • Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2023 · Synced Oct 18, 2026, 5:06 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Adaptive Self-Efficacy-Based AI Coaching for Cycling

NCT07318233
View directory record Official record
Conditions
Exercise Training, Exercise Behavior, Exercise Adherence Challenges, Motivation for Physical Activity, Motivational Enhancement
Interventions
Group 1: Self-efficacy-based AI coaching, Group 2: Static AI Affirmations
Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 18, 2026, 5:06 AM EDT
Terminated Phase 3 Interventional Results available

Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed

NCT00002525
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, leucovorin calcium
Drug
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2015
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 18, 2026, 5:06 AM EDT
Terminated Phase 2 Interventional Results available

Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia

NCT01289678
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Interleukin-2
Drug
Lead sponsor
Leo W. Jenkins Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2016
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 12, 2019 · Synced Oct 18, 2026, 5:06 AM EDT
Terminated Phase 3 Interventional Results available

Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients

NCT01420679
View directory record Official record
Conditions
Peripheral T-cell Lymphoma
Interventions
Pralatrexate Injection
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
3
States / cities
Novi, Michigan • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 19, 2021 · Synced Oct 18, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma

NCT00068393
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma, Renal Cell Carcinoma With Sarcomatoid Features
Interventions
Doxorubicin, Gemcitabine, G-CSF (granulocyte-colony stimulating factor), Neulasta
Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
92
States / cities
Los Angeles, California • Aurora, Colorado • Aurora, Illinois + 56 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2023 · Synced Oct 18, 2026, 5:06 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Sensory-Play Based (SenPlay) Intervention for Young Children With or At Risk for ADHD

NCT05222321
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Sensory-Play Based (SenPlay) Intervention, Spontaneous, Free Play
Other
Lead sponsor
University of Oklahoma
Other
Eligibility
36 Months to 71 Months
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Yukon, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jul 10, 2024 · Synced Oct 18, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

Genetic Variates of Response to Cisplatin, Vinblastine, and Temozolomide (CVT) in Patients With Metastatic Melanoma

NCT00885534
View directory record Official record
Conditions
Melanoma, Skin Cancer
Interventions
Cisplatin, Vinblastine, Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 18, 2026, 5:06 AM EDT
Terminated Not applicable Interventional Results available

Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL

NCT00772668
View directory record Official record
Conditions
Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
Interventions
Rituximab, Bortezomib, Cyclophosphamide, Prednisone
Drug
Lead sponsor
University of Miami
Other
Eligibility
17 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 11, 2017 · Synced Oct 18, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

Phase 1 Study of the Litx™ BPH System in Patients With Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)

NCT00709488
View directory record Official record
Conditions
Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms
Interventions
Talaporfin sodium, Placement of device in prostate urethra, Transurethral illumination with light emitting diodes (Litx™ BPH Device)
Drug · Procedure · Device
Lead sponsor
Light Sciences Oncology
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
6
States / cities
Anchorage, Alaska • Los Angeles, California • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2012 · Synced Oct 18, 2026, 5:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer

NCT01496157
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFBC
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 90 Years · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 18, 2026, 5:06 AM EDT
Recruiting Not applicable Interventional

Acute Genital Nerve Stimulation for Neurogenic Bowel Dysfunction in Individuals Living With Spinal Cord Injury

NCT05626816
View directory record Official record
Conditions
Fecal Incontinence
Interventions
Genital Nerve Stimulation, Clinical exam, Collection of SCI common data elements, Bowel function survey completion, International Standard for Neurological Classification of SCI (ISNCSCI), Response to genital nerve stimulation (GNS), Anorectal Manometry testing (ARM)
Device · Diagnostic Test
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 18, 2026, 5:06 AM EDT
Completed Not applicable Interventional

Reducing Surgical Readmissions Through Mobile Technology

NCT04540315
View directory record Official record
Conditions
Readmission, Perioperative Care
Interventions
MobiMD
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 18, 2026, 5:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Marijuana Approach Bias Retraining and Neural Response in Youth

NCT02723149
View directory record Official record
Conditions
Alcohol Approach/Avoidance Task, Sham Approach/Avoidance Task
Interventions
Marijuana Approach Avoidance Training
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
16 Years to 21 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 18, 2026, 5:06 AM EDT
Completed Not applicable Interventional

Treatment of Intracranial Wide-neck Aneurysms Using Stent-assisted Coil Embolization

NCT04566263
View directory record Official record
Conditions
Intracranial Aneurysms
Interventions
Neuroform EZ Stent System
Device
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 18, 2026, 5:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Improving Pediatric COVID-19 Vaccine Uptake Using an mHealth Tool

NCT05386355
View directory record Official record
Conditions
COVID-19 Vaccines, Telemedicine, Vaccine Hesitancy, Pediatric ALL
Interventions
COVID-19 Vaccine Uptake App, General Health App
Behavioral · Other
Lead sponsor
IDeA States Pediatric Clinical Trials Network
Network
Eligibility
18 Years and older
Enrollment
1,934 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
15
States / cities
Little Rock, Arkansas • Wilmington, Delaware • Honolulu, Hawaii + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 18, 2026, 5:06 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis

NCT05951816
View directory record Official record
Conditions
Systemic Amyloidosis
Interventions
99mTc-p5+14 is an amyloid reactive peptide labeled with technetium-99m., 99mTc-Pyrophosphate
Drug
Lead sponsor
University of Tennessee Graduate School of Medicine
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 18, 2026, 5:06 AM EDT